Objective: To evaluate the efficacy, safety, and clinical outcomes of retrograde intrarenal surgery in a large patient cohort and identify factors affecting treatment success across different demographic groups. Material and Methods: This retrospective study analyzed 3,781 patients who underwent retrograde intrarenal surgery between January 2013 and December 2023. Patient demographics, stone characteristics, operative parameters, and complications were evaluated. Stone-free rates, operative times, and complications were assessed according to stone location and size. The primary outcome was stone-free status evaluated by non-contrast computed tomography at 3 months postoperatively. Multivariate analysis was performed to identify predictors of treatment success. Results: The overall stonefree rate was 88.7%. Mean stone size was 13.9±5.6 mm, with mean operative time of 52 minutes. Stone distribution was: lower calyx (42.5%), renal pelvis (30.0%), upper calyx (15.2%), and middle calyx (12.3%). Total complication rate was 12.5%, with minor complications (ClavienDindo Grade I-II) occurring in 11.4%, moderate complications (Grade III) in 1.0%, and major complications (Grade IV) in 0.05% of cases. Multivariate analysis identified stone size >15mm (odds ratio [OR]: 0.68, p<0.001), lower calyx location (OR: 0.75, p=0.004), and multiple stones (OR: 0.82, p=0.042) as significant predictors of treatment success. Patient satisfaction averaged 8.4 out of 10, showing strong correlation with stone-free status (correlation coefficient: 0.85, p<0.001). Conclusion: Retrograde intrarenal surgery demonstrates high efficacy and safety in treating upper urinary tract stones, with favorable outcomes across different patient groups. Stone size, location, and multiplicity significantly influence treatment success, while complication rates remain low with standardized technique. These findings can aid in optimizing patient selection and improving preoperative counseling.